trevilor 37,5 mg depotkapsel, hård
upjohn eesv - venlafaxinhydroklorid - depotkapsel, hård - 37,5 mg - venlafaxinhydroklorid 42,43 mg aktiv substans; propylenglykol hjälpämne - venlafaxin
trevilor 75 mg depotkapsel, hård
upjohn eesv - venlafaxinhydroklorid - depotkapsel, hård - 75 mg - venlafaxinhydroklorid 84,85 mg aktiv substans; propylenglykol hjälpämne - venlafaxin
phesgo
roche registration gmbh - pertuzumab, trastuzumab - bröst-neoplasmer - antineoplastiska medel - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.
aciclovir 2care4 400 mg tablett
2care4 aps - aciklovir - tablett - 400 mg - aciklovir 400 mg aktiv substans - aciklovir
alfuro 10 mg depottablett
hexal ag - alfuzosinhydroklorid - depottablett - 10 mg - laktosmonohydrat hjälpämne; alfuzosinhydroklorid 10 mg aktiv substans - alfuzosin
alfuro 5 mg depottablett
hexal ag - alfuzosinhydroklorid - depottablett - 5 mg - laktosmonohydrat hjälpämne; alfuzosinhydroklorid 5 mg aktiv substans - alfuzosin
alprazolam 2care4 0,5 mg depottablett
2care4 aps - alprazolam - depottablett - 0,5 mg - laktosmonohydrat hjälpämne; alprazolam 0,5 mg aktiv substans - alprazolam